Google
Trusted Resources: News & Events
Latest announcements and gatherings
Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell Disease
Imara Inc. today announced it will report additional preclinical and Phase 1 clinical data from the company’s lead compound, IMR-687, a once-daily, oral therapy designed to address the underlying pathology of sickle cell disease (SCD). In preclinical studies, IMR-687’s mechanism of action was shown to positively impact both red and white blood cell pathologies associated with the disease. The company has previously reported the ability of IMR-687 to induce fetal hemoglobin (HbF) in murine and human cells at ASH in 2017. Importantly, the data from a recent Phase 1 clinical trial in healthy volunteers demonstrated IMR-687 to be safe and well-tolerated at the target dose that exceeded the effective doses in cell and animal models of SCD, thereby clearing a path to a Phase 2 study in adult patients with SCD. The new data will be presented at the 6th Annual Sickle Cell Therapeutics Conference in New York.
+myBinderRelated Content
-
ASH Clinical Practice Guidelines on Sickle Cell Disease (SCD)https://www.youtube.com/watch?v=tozUcTSN...
-
Preventing Strokes in Children with Sickle Cell Diseasehttps://www.youtube.com/watch?v=k6h7cb7S...
-
A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Seve...Background: Children with severe sickle...
-
Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-...Sickle cell disease (SCD) is a genetic d...
-
100 Years But Only One Drug: Sickle Cell Patients Wait For HelpLast week, 100,000 Americans with sickle...
-
Sancilio Pharmaceuticals Company, Inc. (SPCI) Receives Rare Pediatric Disease Designation From the US Food and Drug ...Sancilio Pharmaceuticals Company, Inc. (...
-
Vaso-Occlusive Pain Linked to Menstruation in Some Patients, Study FindsAcute vaso-occlusive pain is associated ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.